Skip to main content
SPRY logo

SPRY · ARS Pharmaceuticals, Inc.

Track SPRY — free
$3.15 -0.22 (-6.40%)
Market Cap
$337.78M
Shares
100.53M
Volume · Nov 20 988.3K Avg daily vol (3M) 1.81M

Price & Indicators

 

Key stats

Close
$3.36
Thu 19 Nov
Open
$3.70
Thu 19 Nov
Average volume, 30 days
2.2M
shares a session
Short interest
19.0M
18.9% of shares · 11.1 days to cover
Day range
$2.98$3.75
Open $3.70 Close $3.36
52-week closing range
$2.65$13.06
Close $3.36 74.3% under the high
Short volume, last session
48%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Dec 2020 to Nov 2026

Up next

Mar 8, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 5
Earnings call
NEPHE growth supports 2027 break-even and ARS-2 data plan

ARS Pharma reported third-quarter revenue of $37.7 million, including $33.4 million in U.S. NEPHE product revenue, while affirming a path to cash flow break-even by year-end 2027. ARS-2 interim data are expected in the first quarter of 2027.

5 source passages
Earlier today, we issued a press release outlining ARS Pharma's commercial highlights and financial results for the third quarter of 2026. Starting with revenue, total revenue for the third quarter was $37.7 million. In the third quarter, NEPHE continued to capture market share, delivering $33.4 million in U.S. net product revenue. Based on our revised expense plan, we continue to see a path to reaching cash flow break-even by the end of 2027. our Phase 2B trial with ARS-2 is progressing well, and we expect to report interim data in the first quarter of 2027. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
neffy drives revenue growth as net loss widens

ARS Pharmaceuticals reported nine-month 2026 revenue of $94.0 million, versus $56.2 million in 2025, and net loss of $158.5 million. neffy generated $77.1 million in U.S. net product revenue, while cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026.

Revenue $37.71M ▲ 16.0% Net loss $35.59M Diluted EPS -$0.36
Read from the MD&A section
4 source passages
Revenue for the nine months ended September 30, 2026 was $94.0 million, as compared to $56.2 million for the nine months ended September 30, 2025. Net loss for the nine months ended September 30, 2026 and 2025 was $158.5 million and $130.0 million, respectively. Revenue for the nine months ended September 30, 2026 includes $77.1 million in net product revenues for sales of neffy in the United States, $12.8 million in revenue under supply agreements with partners, and $4.2 million in revenue for the achievement of the regulatory and commercial milestones and performance of development and regulatory services under the ALK Collaboration Agreement and the Seqirus Agreement. As of September 30, 2026, we had cash, cash equivalents, and short-term investments of $138.4 million. Open the document at this passage
Nov 5
Current report 8-K
Revenue grew as operating expenses and net loss declined

ARS Pharmaceuticals reported third-quarter revenue of $37.7 million, up from $32.5 million, while operating expenses fell to $71.9 million and net loss narrowed to $35.6 million from $51.2 million.

Financial results
4 source passages
ARS Pharmaceuticals (Nasdaq: SPRY), a commercial biopharmaceutical company focused on needle-free epinephrine, today reported its financial results for the third quarter ended September 30, 2026, as well as recent corporate and commercial highlights. Revenue: Total revenue for the third quarter of 2026 was $37.7 million, consisting of U.S. net product revenue for neffy of $33.4 million, supply revenue of $2.6 million and collaboration revenue of $1.7 million. This compares with total revenue of $32.5 million for the third quarter of 2025, which included U.S. net product revenue of $31.3 million. Total Operating Expenses: Third-quarter 2026 total operating expenses were $71.9 million, including stock-based compensation of $8.1 million. Net Loss: Net loss for the third quarter of 2026 was $35.6 million, or $(0.36) per share, compared with a net loss of $51.2 million, or $(0.52) per share, for the third quarter of 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$122.14M
Trailing 12 months
Net income (TTM)
−$199.87M
Trailing 12 months
Revenue growth YoY
+16.0%
Year over year
Operating margin
-161.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-54.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$16.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-52.6%
Trailing year
Short interest
18.9%
Latest settlement · 11.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. NEPHE revenue, market share, prescriber reach and financial discipline improved. Risks include continued net losses, higher R&D spending, inventory-related revenue volatility, coverage gaps and delayed commercial benefits, alongside an ARS-2 interim data catalyst in the first quarter of 2027.

Bullish
  • + NEPHE U.S. net product revenue increased to $33.4 million from $31.3 million. new
  • + Total U.S. NEPHE market share increased to 5% from 4% year over year. new
  • + Field-targeted market share rose to approximately 9% from 6% year over year. new
  • + Quarterly unique prescribers increased 49% to 19,605. new
  • + Q3 SG&A fell to $43.5 million from $74.8 million. new
  • + ARS-2 Phase 2b interim data are expected in the first quarter of 2027, with full data later in 2027 informing a potential Phase 3 program. new
Bearish
  • − The company remained unprofitable, with a Q3 net loss of $35.6 million. new
  • − R&D expenses increased to $18.3 million from $2.8 million, primarily due to a one-time license payment. new
  • − NEPHE share remained only 2% in non-targeted accounts. new
  • − Net revenue growth lagged end-user demand because of inventory-related changes. new
  • − Coverage gaps remain in the remaining Medicaid states and commercial plans. new
  • − Benefits from the commercial reset were not expected to become increasingly visible until the first half of 2027. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −51%
below
Price vs 50-day avg −15%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 7%
near low
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −64%
trailing
YTD return −71%
this year
Relative strength −59%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.89% of shares out · ▼ -4.2% MoM · 11.1 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
191 holders — mid 3-yr range
Squeeze score 70
high risk · 0–100
Fundamentals
Poor
Revenue growth −5%
Y/Y
EPS growth −2275%
Y/Y
Free cash flow $-171.2M
Balance sheet $55.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −80%
past year
ATR 11.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
Aggregate SG&A and R&D expenses, including stock-based compensat · second half 2026 $114M – $126M
Previous outlook earlier release · from the 8-K filed Aug 13, 2026

Still-open targets the latest release did not restate under the same label.

SG&A cash-based expenses · from the first half of 2026 at least 40%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−51% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.89% of shares out · ▼ -4.2% MoM · 11.1 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
191 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 7% Range high $13
vs 200-day avg -51% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and short-term investments $138.4M As of September 30, 2026 —
Prescriber base 19,605 the third quarter of 2026 —
Total U.S. market share 5% the third quarter of 2026 —
Total U.S. epinephrine market share 5% Q2 2026 —
Unique prescribers 16,000 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SPRY
ARS Pharmaceuticals, Inc.
this stock
$337.78M -71.2% -5.5% — 18.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
191
% held
88.1%
Net QoQ
-2.1M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
135
View
Short & Settlement
Short Interest Falling
Shares short
19.0M
Days to cover
11.1d
Change
-829.2K sh
View
Short Volume
Short vol %
48%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3.8K
Value
$14.3K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
42.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$84.3M
Net income (FY)
$-171.3M
EPS diluted
$-1.74
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
15

ARS Pharmaceuticals reported nine-month 2026 revenue of $94.0 million, versus $56.2 million in 2025, and net loss of $158.5 million. neffy generated $77.1 million in U.S. net product revenue, while cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026.

View
Proposed Sales
Value
$402.4K
Shares
139.6K
Filed
Nov 9, 2026
View
Exempt Offerings
Offering
$85.0M
Filed
Oct 6, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
ARS Pharma Reports Business Highl…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
SPRY -11.8% -22.2% -64.4% -0.6% -71.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -6.4% -15.9% -58.7% +4.7% -76.1%
Key facts CIK 1671858 CUSIP 82835W108 13F (30d) 206 filings 181 filers Visit website Investor relations